## Review setup
- **Input scope** Abstract only
- **Assessment boundary** Claims and evidence presented in the abstract; no figures, tables, methods, or supplementary materials were provided
- **Shared manuscript claim summary** The authors propose that a subset of T1D-associated genetic variants disrupt transcription factor binding at cell type-specific candidate cis-regulatory elements in human pancreatic islets, thereby altering gene expression and contributing to β-cell dysfunction. They integrate public epigenomic and single-cell multiomic datasets with T1D GWAS variants, apply ChromBPNet to predict variant effects on chromatin accessibility, and use TF footprinting to nominate transcription factors. They report identification of several T1D-associated SNPs predicted to alter chromatin accessibility at candidate TF binding sites.
- **Visible evidence base** Abstract text only; no quantitative results, validation metrics, or dataset identifiers beyond PANC-DB and ChromBPNet are provided
- **Missing materials affecting confidence** Full manuscript, all figures and tables, methods details, model training and evaluation procedures, variant lists, statistical thresholds, and any validation experiments

## Reviewer
- **Overall assessment** The abstract presents a plausible and potentially valuable analytical framework for linking T1D-associated noncoding variants to cell type-specific regulatory effects in pancreatic islets. The integration of public epigenomic data with GWAS variants and deep learning-based accessibility prediction is methodologically current. However, the abstract provides no quantitative evidence, no validation of predictions, and no demonstration that the identified variants have functional consequences. The core claim that specific SNPs "may contribute to β-cell dysfunction" remains speculative and is not supported by the evidence presented in the abstract. The work is at a hypothesis-generating stage and would require substantial additional evidence to establish a mechanistic case.
- **Who would be interested in the results, and why** Geneticists and epigenomics researchers studying autoimmune disease risk variants, particularly those focused on type 1 diabetes and pancreatic islet biology. Investigators working on the functional interpretation of noncoding GWAS variants and those developing computational pipelines for variant effect prediction would also find the approach relevant. The potential link between β-cell-intrinsic regulatory variation and T1D pathogenesis could interest the broader diabetes research community.
- **Major strengths** The study addresses an important gap in understanding how T1D-associated variants may act through β-cell-intrinsic mechanisms. The integration of multiple public datasets, including single-cell multiomic data, is appropriate for the question. The use of ChromBPNet for base-pair-resolution prediction is a current and technically suitable approach. The focus on cell type-specific regulatory programs is well motivated by the biology of T1D.
- **Major Concerns**
  - **Concern ID** R1-M1
  - **Severity** Major
  - **Blocking** Yes
  - **Axis** Evidence sufficiency
  - **Claim pointer** The authors claim that "several T1D-associated SNPs predicted to alter chromatin accessibility at candidate TF binding sites" were identified, and that these findings "link T1D-associated variants to cell type-specific enhancer activity and regulatory pathways."
  - **Evidence pointer** Abstract only; no figures or tables provided
  - **Concern** The abstract reports the identification of SNPs predicted to alter chromatin accessibility but provides no quantitative information. No number of variants identified, no effect sizes, no statistical significance thresholds, no comparison to control variants, and no assessment of prediction confidence are given. Without these data, the reader cannot evaluate whether the findings exceed what would be expected by chance or whether the predictions are biologically meaningful.
  - **Why it matters** The central claim of the paper rests on the identification of specific variants with predicted regulatory effects. If the predictions are not benchmarked against known functional variants or validated experimentally, the results may represent false positives from a computational pipeline. The absence of any quantitative evidence prevents assessment of the robustness and specificity of the findings.
  - **Resolution test** Provide the number of T1D-associated SNPs tested, the number predicted to alter accessibility, the distribution of predicted effect sizes, and a comparison against matched control variants. Include validation metrics for ChromBPNet performance on islet data and, ideally, experimental validation of at least one or two top candidate variants.
  - **Concern ID** R1-M2
  - **Severity** Major
  - **Blocking** Yes
  - **Axis** Functional validation
  - **Claim pointer** The authors state that their findings "suggest mechanisms by which noncoding variants may contribute to β-cell dysfunction and T1D susceptibility."
  - **Evidence pointer** Abstract only; no experimental data described
  - **Concern** The abstract describes only computational predictions. No experimental evidence is presented to show that any identified variant actually alters TF binding, chromatin accessibility, or gene expression in relevant cell types. The leap from predicted regulatory effects to a claim about contribution to β-cell dysfunction is not supported by the evidence described.
  - **Why it matters** Computational predictions of variant effects on regulatory elements are known to have substantial false positive rates. Without experimental validation, such as reporter assays, electrophoretic mobility shift assays, or CRISPR-based perturbation in stem cell-derived β cells or islet models, the biological relevance of the identified variants remains unestablished. The claim of a mechanistic link is therefore premature.
  - **Resolution test** Include experimental validation for at least a subset of top candidate variants demonstrating allele-specific effects on TF binding, enhancer activity, or gene expression in a relevant cellular context. Alternatively, provide strong orthogonal evidence such as allele-specific accessibility or expression quantitative trait loci data from primary human islets.
  - **Concern ID** R1-M3
  - **Severity** Major
  - **Blocking** No
  - **Axis** Methodological transparency
  - **Claim pointer** The authors state that they "integrated publicly available epigenomic datasets" and "combined these data with T1D GWAS variants to identify disease-associated SNPs located within enhancer regions."
  - **Evidence pointer** Abstract only; dataset identifiers and analysis details not provided
  - **Concern** The abstract does not specify which GWAS dataset was used, how linkage disequilibrium was handled, which epigenomic marks defined enhancers, how cell type-specific cCREs were called, or how the multiomic datasets from PANC-DB were processed. The criteria for selecting candidate variants for ChromBPNet analysis are not described.
  - **Why it matters** The reproducibility and validity of the findings depend critically on these methodological choices. Different GWAS datasets, LD thresholds, and enhancer definitions could substantially change the set of candidate variants identified. Without this information, the results cannot be evaluated or reproduced.
  - **Resolution test** Provide a detailed methods section specifying all data sources, quality control procedures, analysis parameters, and thresholds. Include a flowchart or schematic of the analytical pipeline.
- **Minor Comments**
  - **Concern ID** R1-m1
  - **Severity** Minor
  - **Axis** Clarity
  - **Affected element** Terminology
  - **Evidence pointer** Abstract, first paragraph
  - **Issue** The phrase "candidate cis-regulatory elements (cCREs)" is used without defining the criteria for what constitutes a "candidate" element in this context.
  - **Required correction** Define cCREs explicitly, including the epigenomic marks and thresholds used to call them.
  - **Concern ID** R1-m2
  - **Severity** Minor
  - **Axis** Completeness
  - **Affected element** TF nomination
  - **Evidence pointer** Abstract, methods description
  - **Issue** The abstract states that TF footprinting was used to "nominate TFs likely to bind these variant-containing regions" but does not indicate whether the nominated TFs are known to be expressed in the relevant islet cell types.
  - **Required correction** State whether TF expression in the relevant cell types was confirmed using the available single-cell data.
  - **Concern ID** R1-m3
  - **Severity** Minor
  - **Axis** Interpretation
  - **Affected element** Causal direction
  - **Evidence pointer** Abstract, final sentence
  - **Issue** The abstract implies that altered chromatin accessibility at variant sites would lead to β-cell dysfunction, but the direction of causality is not established. Altered accessibility could be a consequence of disease state rather than a cause.
  - **Required correction** Acknowledge the correlational nature of the findings and discuss the possibility that accessibility changes reflect rather than drive disease processes.
- **Technical failings that need to be addressed before the case is established** R1-M1 and R1-M2 are the primary technical concerns. The absence of quantitative results and the lack of any experimental or orthogonal validation mean that the central claims of the paper are not currently supported. R1-M3 regarding methodological transparency must also be addressed to allow evaluation of the analytical approach.
- **Assessment against Nature-style criteria**  
  Originality: The combination of public epigenomic integration, single-cell multiomic analysis, and deep learning-based variant effect prediction applied specifically to T1D islets has elements of novelty, though each individual component is established in the field.  
  Scientific importance: The question of how T1D risk variants act through β-cell-intrinsic mechanisms is important and timely. If the findings are robust, they could inform understanding of disease pathogenesis.  
  Interdisciplinary readership: The work would appeal to geneticists, epigenomics researchers, and diabetes biologists, but the abstract as written is unlikely to attract a broader readership without clearer articulation of biological significance.  
  Technical soundness: Cannot be assessed from the abstract alone. The absence of quantitative results and validation is a major limitation.  
  Readability for nonspecialists: The abstract is reasonably clear but uses specialized terminology without sufficient context. The logical flow from hypothesis to methods to findings is understandable.
- **Recommendation posture** Currently not established from the provided evidence. The analytical framework is promising and the question is important, but the abstract provides no quantitative support for the central claims and no validation of the computational predictions. The manuscript would need to include detailed results, benchmarking, and ideally experimental validation before the case for a mechanistic link between T1D variants and β-cell dysfunction can be considered.

## Risk / unsupported claims
- The claim that "several T1D-associated SNPs predicted to alter chromatin accessibility at candidate TF binding sites" were identified is unsupported because no quantitative results are provided.
- The claim that the findings "suggest mechanisms by which noncoding variants may contribute to β-cell dysfunction" is unsupported because no functional validation or causal evidence is presented.
- The claim that the identified variants "link T1D-associated variants to cell type-specific enhancer activity and regulatory pathways" is not evaluable without details on the enhancer definitions and variant selection criteria.
- The overall hypothesis that T1D-associated variants directly influence cCREs by disrupting TF binding is plausible but remains unverified by the evidence described in the abstract.